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Abstract
Background: Current smoking cessation treatments focus on addressing the pharmacological dependence of
smokers on nicotine. However, new strategies are needed that address both nicotine dependence and the
psychological dependence on cigarettes as the source of nicotine. Evidence from a number of small smoking
cessation studies suggests that the use of cigarettes with reduced nicotine content, in combination with nicotine
replacement therapy (NRT), may help reduce withdrawal symptoms and increase quit rates. This paper describes
the protocol for a large randomised-controlled trial to test the effect of using nicotine-free cigarettes together with
NRT on long-term quit rates.
Methods/design: This single-blind, randomised trial aims to recruit 1,410 participants through the national
telephone-based Quitline service in New Zealand. Participants in the treatment arm will be asked to stop smoking
nicotine-containing cigarettes on their chosen Quit day and smoke ad libitum nicotine-free (Quest 3) cigarettes for
six weeks. At the same time people in this group will be asked to start using NRT patches, gum and/or lozenges
(as recommended by Quitline) for eight weeks. Participants in the control arm will be asked to stop smoking
completely on their chosen Quit day and start using NRT patches, gum and/or lozenges (as recommended by
Quitline) for eight weeks. Data collection will occur at baseline, three and six weeks, and three and six months after
Quit day. The primary outcome is the proportion of participants who self-report seven-day point prevalence
abstinence at six months since Quit date.
Discussion: Smoking prevalence in New Zealand has changed little in recent years (particularly in Māori, the
indigenous people of New Zealand) and additional options for smokers who want to quit are needed. Although a
variety of methods are available to help, many are expensive, have side effects, and despite their use most quit
attempts still fail. This trial will test the balance of benefits and risks of a new strategy for people to overcome
nicotine dependence. Since smoking is the leading cause of lost healthy life years in New Zealand, if proven
effective this strategy is likely to have substantial public health benefits.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12608000410358
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Background
Smoking is the leading cause of lost healthy life years in
New Zealand. In 1990, 28% of New Zealand adults
smoked, with this figure dropping to 24.9% in 1996/7,
24.5% in 2002/3 [1] and 19.7% in 2006/7 [2]. In Māori
(indigenous New Zealanders) there has been little down-
ward trend in smoking prevalence since the early 1990’s,
with 45.5% of Māori smoking in 1996/7, and 47.2%
smoking in 2002/3 [2]. However, in 2006/7 there was
a sharp fall in smoking prevalence in Māori, down to
38% [2]. Despite this recent evidence of change, based on
the current rate of progress it is estimated that it will
take 100 years before the adult smoking rates in New
Zealand reach 3.6%, the level of all New Zealand doctors
now smoking [3]. New approaches to smoking cessation
are urgently needed, ideally ones that give additional ben-
efits to existing strategies. One approach that warrants
further investigation is to look at ways of reducing the
association between smoking and nicotine delivery.
Nicotine is the constituent of tobacco principally
responsible for the addictive nature of cigarette smok-
ing. Reward pathways in the brain are stimulated within
two to three minutes of inhalation. The smoker is com-
pelled to continue dosing throughout the day to main-
tain the desirable effects of nicotine and mitigate
feelings of withdrawal [4]. Other factors, besides nico-
tine, may also play a part in the dependency-forming
aspects of smoking, including the effects of other chemi-
cals in tobacco smoke, the strong behavioural/tactile
association of smoking and the social pleasure of
smoking.
There is some evidence that progressive reduction in
the level of nicotine in cigarette tobacco can reduce the
level of nicotine dependence in smokers, with minimal
compensatory smoking and without any negative health
effects [5]. Reduced nicotine cigarettes have been pro-
duced in the past (as the Quest brand marketed by Vec-
tor Tobacco Inc, USA), with the tobacco altered
through genetic modification. Quest 1, 2 and 3 cigar-
ettes have a nicotine yield of 0.6 mg, 0.3 mg and
≤0.05 mg per cigarette respectively, an average nicotine
content of 8.9 mg, 5.1 mg and 1.0 mg per cigarette
respectively, and a tar content of 10 mg per cigarette
(similar to the level in regular cigarettes). These cigar-
ettes are no longer commercially available, but are avail-
able for research purposes. The use of Quest 3
cigarettes, so called nicotine-free cigarettes, warrant
further scientific investigation, as current evidence sug-
gests that the use of nicotine replacement therapy
(NRT) in combination with such cigarettes may have a
greater impact on the signs and symptoms of withdra-
wal and cessation rates, compared to the use of nico-
tine-free cigarettes alone [5]. However, there is a need to
undertake adequately powered clinical trials to clarify
the true strength and direction of the above association,
with at least six months follow-up data collected.
Methods/design
Objectives
The primary objective of this trial is to determine the
combined effect of nicotine-free cigarettes and NRT
(used immediately after quitting), on long-term quit
rates. Secondary objectives include whether such an
intervention is cost effective and acceptable.
Study design
This study is a parallel, randomised controlled clinical
trial, with allocation concealed from the study
researchers.
Study population
The study population will be registered and eligible call-
ers to the national toll-free Quitline cessation service.
Inclusion criteria
Participants will be smokers from throughout New Zeal-
and who want to stop smoking. Participants will be eli-
gible provided they: are at least 18 years of age, have
their first cigarette within 30 minutes of waking, are
able to provide verbal consent, and have a telephone.
Exclusion criteria
Pregnant women and women who are breastfeeding will
be excluded from the trial. People will also be excluded
from the trial if they meet any of the following criteria:
current users of NRT products; current clients of
Txt2Quit and NRT Online (current Quitline services);
current users of non-nicotine based cessation therapies
(e.g. buproprion, clonidine, nortriptyline or varenicline);
they only use non-cigarette tobacco products (e.g. pipes,
cigars); they have had a myocardial infarction within the
last two weeks; and have had angina, severe cardiac
arrhythmia or a stroke in acute phase within the last
two weeks. The medical conditions above are listed con-
traindications for the use of NRT patch, gum, and
lozenge. A number of disease conditions are known
where precautions for the use of NRT products are indi-
cated, such as severe cardiovascular disease (occlusive
peripheral arterial disease, cerebrovascular disease, stable
angina pectoris, and uncompensated heart failure) and
vasospasm, uncontrolled hypertension, renal or hepatic
impairment, active duodenal ulcers and gastric ulcers.
Quitline staff will ask potential participants about these
conditions, prior to participant randomisation.
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Randomisation: allocation concealment and sequence
generation
All potential participants will be assigned a unique regis-
tration number allocated by a central computer following
details submitted on a web-based form. This number will
be used to identify each randomised participant who has
consented to take part. Participants will be randomised
by computer, with stratified minimisation by sex, ethni-
city (Māori, non-Māori), and level of nicotine depen-
dence (> 5 points, ≤ 5 points on the Fagerström Test of
Nicotine Dependence (FTND) Questionnaire [6]), to
ensure a balance in these key prognostic indicators
between the intervention and control group.
Blinding
Due to the nature of the intervention only single blinding
(of researchers, not of participants) is possible in this trial.
Members of the trial steering committee, management
committee, and other team members from the Clinical
Trials Research Unit (with the exception of the project co-
ordinator and the Quitline research manager) will remain
blinded to treatment allocation until the code is broken
(after the last follow-up call is completed and the data
recorded). The project co-ordinator will not be blinded as
they will be responsible for distributing the nicotine-free
cigarettes to participants. The research manager and
research assistants based at Quitline will not be blinded to
treatment allocation, as they are required to know which
group each participant has been allocated to in order to
conduct the scheduled follow-up calls.
Study intervention
Participants will be randomised to a six week interven-
tion of nicotine-free cigarettes (Quest 3) plus eight
weeks of usual care (NRT plus behavioural support) ver-
sus eight weeks of usual care (NRT plus behavioural
support).
• Treatment group: Participants allocated to the
treatment arm will be asked to stop smoking their
normal cigarettes on their chosen Quit day and
switch to the nicotine-free cigarettes (Quest 3) cour-
iered to them, then at six weeks to stop smoking the
nicotine-free cigarettes (Figure 1). Participants will
be told that they should try all the techniques sug-
gested by the Quitline advisors to help them get
through the withdrawal period (i.e. drink water, deep
breathe, do something else, delay), but if they still
feel they must have a cigarette, they should only
smoke the nicotine-free cigarettes provided. Partici-
pants will also be supported by Quitline in the usual
way for eight weeks, with counselling/advice and
NRT in the form of a patch, gum and/or lozenge
(Figure 1). The Quest 3 cigarettes used in this trial
have recently been reformulated by Vector Tobacco
Inc and no longer contain genetically modified
tobacco. The “new” cigarettes still have a similar
nicotine content (1.5 mg per cigarette) and yield
(≤ 0.05 mg per cigarette) as the original Quest 3 cigar-
ettes, but the tar content has been reduced from 10mg
to 4mg per cigarette. In order to verify the nicotine
Treatment group      
 
          
    
Control group
NRT = Nicotine Replacement Therapy 
Nicotine-free cigarettes
(≤ 0.05 mg nicotine)
NRT patch, gum and/or lozenge and usual support
8 weeksRandomisation
and Quit day
6 weeks
NRT patch, gum and/or lozenge and usual support
3 weeks
Figure 1 Schematic of treatment allocation during intervention period.
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and tar content of the trial cigarettes, independent ver-
ification will be undertaken by Labstat Canada. Specifi-
cally, the nicotine content of the unburnt nicotine-free
cigarettes will be assessed (including analysis of nico-
tine alkaloids by gas chromatography and tobacco
moisture), as will total particulate matter, water, nico-
tine, particulate matter (water and nicotine free), car-
bon monoxide and puff number.
• Control group: Participants allocated to the control
arm of the trial will be asked to stop smoking com-
pletely on their chosen Quit day and will be sup-
ported by Quitline in the usual way for eight weeks,
with counselling/advice and NRT in the form of a
patch, gum and/or lozenge (Figure 1).
Current standard cessation practice at the New Zealand
Quitline (as at December 2010) is as follows (other cessa-
tion providers in New Zealand do not follow the process
outlined here): Quitline issues by post, a Quit Card (with
a 90 day expiry) for eight weeks supply of up to three
NRT products (patch, gum and/or lozenge) and makes
routine support calls by telephone over eight weeks.
These support calls are administered by the Quitline
advisors as required. Quitting support generally involves
an average of three follow-up telephone calls, each lasting
about 10-15 minutes. However, if people do not wish to
receive support calls, they are not scheduled but callers
are advised that they can phone Quitline at any time for
support. Participants are advised to take the Quit Card to
a pharmacist in exchange for subsidised patches, gum
and/or lozenges (NZ$3 per item per four-week course of
NRT). The strength of NRT patch, gum, and/or lozenges
to be used by each participant is determined by the Quit-
line advisor (as per their dosage guidelines) as to the
degree of each person’s nicotine dependency. “Quit day”
in this study will refer to the day each participant stops
smoking cigarettes containing nicotine.
Baseline assessments
Participants from throughout New Zealand will call
Quitline seeking advice and wishing to enrol in the
Quitline smoking cessation programme. A Quit advisor
from Quitline will undertake the standard Quitline
assessment. A list of those individuals who indicate that
they wish to take part in research will be transferred
from the Quitline database to the trial research assis-
tants based at Quitline. The research assistants will
attempt to make contact with people on the list. Those
contacted will be told about the trial and asked if they
would like to participate. If the potential participant
indicates that they are interested, they are consented
and asked for demographic data (age and sex) and
checked to see if they meet the inclusion criteria for the
trial. For those that do meet the inclusion criteria,
further details will be collected about the participant’s
ethnicity and level of nicotine dependence (as deter-
mined by the FTND Questionnaire [6]) and they will be
randomised Data from this initial assessment will then
be electronically transferred (securely) to the Clinical
Trials Research Unit’s Oracle database. The research
assistant will then collect the following baseline data
from each participant over the telephone.
• Demographic information: Socio-economic posi-
tion, based on income, education and occupation.
• Smoking history: Age when started, number of
cigarettes smoked per day, number of years as regu-
lar smoker, number of previous unsuccessful
attempts to give up in past 12 months and the
method used, other types of smoking (pipe, cigar),
usual brand/pack size (and how long pack lasts), and
type of cigarettes smoked per day (e.g. roll-your-own
or factory-made).
• Other smoking related information: Self-rated
chances of quitting (measured on a scale of one to
five, where one is very low and five is very high),
household smoking, smoking in cars.
• Concomitant medication: Information about types
of medication currently used will be collected.
• The physical signs and symptoms associated with
withdrawal: Measured using the Mood and Physical
Symptoms Scale (MPSS) [7]. Additional withdrawal
questions will also be asked related to the frequency
of disturbed sleep, anxiety, mouth ulcers, cough,
impatience, dizziness and increased dreaming [8].
• Alcohol use and abuse: Measured using the Alco-
hol Use Disorders Identification Test (AUDIT-C), a
screening tool that helps to identify people who are
hazardous drinkers or have active alcohol use disor-
ders (including alcohol abuse or dependence) [9].
Outcome measures
Primary outcome
The proportion of participants who self-report having
stopped smoking at six months after their Quit date.
‘Stopped smoking’ will be defined as having consumed
no nicotine cigarettes (not a single puff) in the previous
seven days (seven-day point prevalence).
Secondary outcomes
The following secondary outcome measures will be
assessed at three and six weeks after the Quit date in
the treatment group only:
• Information related to the use of the nicotine-free
cigarettes: Participants will be asked for their views
on the use of the nicotine-free cigarettes (including
concerns, whether they liked the taste of them, etc),
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and whether the six weeks use of the cigarettes was
adequate. The number of nicotine-free cigarettes
and normal cigarettes smoked each week during the
intervention period will also be recorded.
• Information related to the use of the NRT: Partici-
pants will be asked about their use of NRT during
the treatment period.
The following secondary outcome measures will be
assessed in all participants at three weeks, six weeks,
three months and/or six months after the Quit date:
• The physical signs and symptoms associated with
withdrawal at three and six weeks: Measured using
the Mood and Physical Symptoms Scale (MPSS) [7].
Additional withdrawal questions will also be asked
related to the frequency of disturbed sleep, anxiety,
mouth ulcers, cough, impatience, dizziness and
increased dreaming [8].
• Self-rated chances of quitting at three and six
weeks: Measured on a scale of one to five, where
one is very low and five is very high.
• Proportion of participants who have stopped
smoking at three weeks, six weeks and three months:
Defined as no nicotine cigarettes (not even a puff) in
the past seven days.
• Continuous abstinence: Defined as self-report of
smoking no more than five nicotine cigarettes from
the Quit date, collected at all time points.
• Proportion of participants who have significantly
reduced daily smoking level at six months: Defined
as reducing consumption by at least 25% (in terms
of numbers of cigarettes per day or weight of loose
tobacco per day).
• Number of cigarettes currently smoked per day: If
the participant is still smoking (all times points).
Pack size (and how long pack lasts) if smoking roll-
your-owns.
• Cost information: Cost outcomes will include cost
per quitter, cost per person reducing their daily
cigarette consumption, and cost per Quality
Adjusted Life Year of life saved among quitters. The
tobacco expenditure savings to individual smokers
will also be calculated using data on the daily
amount smoked prior to quitting and the price of
the particular products smoked.
• Use of NRT: Participants will be asked about con-
tinued use of any NRT (including type, dosage, fla-
vour, and frequency of use) at all time points.
• Use of non-NRT methods of cessation at six
months: Participants will be asked about their use of
non-NRT methods of cessation such as buproprion,
clonidine, nortriptyline, varenicline, acupuncture etc.
• Alcohol use and abuse at six months: Measured
using the AUDIT-C [9].
• Serious adverse events: Information regarding any
serious adverse events and whether they are related
to treatment will be collected at all time points.
• Concomitant medication: collected at all time
points
Sample size
A sample size of 1,410 people (705 in each group, with a
loss to follow-up rate of 20% and at least 25% Māori in
the sample) is required for this trial. This number will
provide 90% power at p = 0.05 to detect a difference in
point prevalence abstinence of 7.5% at six months. In
addition, this sample size will allow the consistency of
effects for pre-specified subgroups to be assessed. It is
expected to take 18 months to recruit the required sam-
ple size, based on a previous cessation trial run through
the New Zealand Quitline [10].
Withdrawal criteria
If, at any time after randomisation, significant intoler-
ance to the study treatment is suspected, the treatment
(or control) can be withdrawn. Should participants
require discontinuation of study treatment for any rea-
son (see below), or if they elect to cease taking treat-
ment, follow-up calls and data collection will continue
as scheduled as if they were continuing with the rando-
mised treatment. Participants may have the study treat-
ment withdrawn if one or more of the following occurs:
• The participant makes a voluntary decision to
withdraw from follow-up, or from the treatment.
• The participant has any serious clinical adverse
event, intercurrent illness, or other medical condi-
tion that indicates to the principal investigator that
continued treatment with the study treatment is not
in the best interest of the participant. The study
treatment will be withdrawn if the participant devel-
ops any life threatening or seriously disabling illness
or is admitted to hospital.
• The participant becomes pregnant during the
course of the trial. Such participants will be asked to
discuss on-going NRT use with their general practi-
tioner or lead maternity caregiver.
• The investigator feels that it is in the best interests
of the participant.
• The study is terminated.
If the participant discontinues treatment due to a ser-
ious adverse event, the participant will be followed until
the event resolves or there is a return to a clinically
acceptable medical status. Participant deaths or serious
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adverse events, which occur within 30 days of disconti-
nuation, will be reported to the project co-ordinator.
Data management
The design and management of all databases associated
with this trial will be undertaken by the data manage-
ment and information technology groups at the Clinical
Trials Research Unit. Data will be stored in the Unit’s
Oracle database and linked to the electronic Case
Record Form (CRF) data where applicable. Validation
rules for each CRF will be specified by the project co-
ordinator, in association with the senior data manager.
These rules will include range checks so that inaccura-
cies in data collection can be identified early. A query
will be raised as soon as any values are entered that are
outside the allowed range or if data are missing. The
research assistants at Quitline will amend the form as
soon as a query is raised.
Data monitoring
An independent person will monitor the trial conduct.
This monitor will audit Quitline and the Clinical Trials
Research Unit during the trial to ensure that the study
protocol is being adhered to. At Quitline the monitor
will audit every randomised participant’s records to
ensure their existence, that they meet the inclusion cri-
teria and have provided informed consent, and that the
treatment is being distributed within the limits of the
protocol. The monitor will review the study documenta-
tion and records held by Quitline to ensure that docu-
mentation is up-to-date and record keeping meets the
requirements specified in the protocol and complies
with regulatory requirements. The monitor will visit
Quitline early on during the study (after ten participants
have been randomised), at study close-out and twice
during the course of the trial. The monitoring task for
the trial is unlikely to be onerous as the majority of data
for this trial will be collected electronically, with range
and logic checks built into the programme used. In the
rare event that the computer programme is not accessi-
ble (e.g. power cut, system down), hard copies of the
CRF’s will be completed by the research assistants at
Quitline, with the data entered onto the Unit’s computer
database at a later stage. Hard copies of the CRF’s will
be checked for consistency by the monitor and checked
against the electronic copy. The monitor will audit the
Unit every three months to see that the product supply
records are in order and that there are sufficient sup-
plies remaining, that the nicotine-free cigarettes are
being stored appropriately and that the handling of
unused nicotine-free cigarettes complies with study pro-
cedures. A Data Safety and Monitoring Committee has
not been established for this trial as the trial does not
meet two or more of the criteria stipulated by Ellenburg
el al (2002), for setting up such a committee [11].
Data analyses
This trial has been designed with the assistance of a
senior statistician at the Clinical Trials Research Unit,
who will continue to advise and assist with analyses of
the trial data.
Treatment effects
Analyses will be undertaken on an intention-to-treat
basis, according to a pre-specified statistical analysis
plan using SAS version 9.1.3. A per-protocol analysis
will also be performed in order to check the robust-
ness of the results. No interim analysis will be underta-
ken. Chi-squared analyses will be used to compare the
proportion quit by treatment group, and incidence
rates, relative risks, risk differences, 95% confidence
intervals and two-sided p-values will be calculated.
Logistic regression analyses will be utilized to adjust
for important prognostic factors. Continuous outcome
data will be analysed using multiple linear regression
modelling. Both the number of cigarettes per day and
withdrawal symptoms over time will be compared
using analysis of covariance. Pre-specified subgroup
analyses using tests for heterogeneity will be underta-
ken for ethnicity (Māori, non-Māori), age (< 40 years,
≥ 40 years), sex and socioeconomic status (dichoto-
mised as those who left school below Year 12 or with
no school qualification, and those who completed Year
12 and above). Analyses will also be undertaken to
examine time-to-first-lapse using Kaplan-Meier analy-
sis and self-reported seven-day point prevalence of
smoking abstinence at six months in those with com-
plete smoking status data.
Cost analyses
Costs analyses will be undertaken if a statistical differ-
ence between the groups is observed for the primary
outcome of interest. Cost outcomes will include cost
per quitter, cost per person reducing their daily cigar-
ette consumption, and cost per quality adjusted life
year of life saved among quitters (using discount rates
of 0%, 5% and 10%). These data will then be compared
with New Zealand data from Quitline and other NRT
service providers, in addition to information from var-
ious international studies. This modelling will take a
health sector perspective. However, the tobacco expen-
diture savings to individual smokers will also be calcu-
lated (for those who quit and cut down) to give a
more societal perspective on the benefits (especially to
low-income smokers). This calculation will use data on
the daily amount smoked prior to quitting and the
price of the particular products smoked. For those who
cut down their consumption by a significant margin
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(i.e. 25% or more), the cost per person reducing their
daily cigarette consumption will be calculated. Differ-
ent approaches to assessing the benefit of years per life
saved - including the use of New Zealand specific data
on the relative risk of death as per Hunt et al 2005
[12], will also be explored.
Tolerability
All randomised participants who receive at least one
dose of study treatment or control will be included in
the planned analyses. Comparison of the frequency of
treatment withdrawal between the treatment and the
control group will be tested using Chi-square statistics.
The numbers of participants discontinuing treatment
prematurely for any reason will be summarised by treat-
ment group and by reasons for discontinuation. Serious
adverse events will be coded using ICD-10 AM codes.
The incidence of all suspected serious adverse treatment
reactions will be summarised by treatment group.
Procedures to account for missing data
For treatment effects, sensitivity analysis will be carried
out to determine the effect of missing data (such as par-
ticipants lost to follow-up). All participants lost to fol-
low-up will be presumed to be smoking [13].
Ethics
Ethics approval has been granted from the National
Multi-Regional Ethics Committee (Ethics number MEC/
08/10/117). Maintenance of confidentiality and compli-
ance with New Zealand’s Privacy Leglisation will be
emphasised to all study participants. Participation in the
study is entirely voluntary. Verbal consent will be
obtained at the time of contact with Quitline, however a
written consent form and patient information sheet will
be posted out to participants for their information. Data
will be entered, stored and backed-up in a secure man-
ner via the Unit’s internet data management system.
Participants will be acknowledged in all publications and
presentation of the results.
Discussion
Increasing quit rates would have a significant positive
impact upon the health and well-being of smokers and
their households [14]. Unfortunately many smoking
cessation aids on the market are relatively expensive,
have side effects and are only moderately efficacious.
There would be great interest in a novel smoking ces-
sation aid that may be an addition to current therapies
or indeed could be used by those who do not want to
or can’t use NRT or other cessation pharmacothera-
pies. Initial studies have shown that reduction in expo-
sure to nicotine in cigarettes can reduce the level of
nicotine dependence in smokers, at least in the short
term, and that combined use of reduced nicotine cigar-
ettes and NRT appears more effective at increasing
quit rates than using reduced nicotine cigarettes alone
or NRT alone [5]. However, larger and more long-term
studies are still needed to clarify the strength of this
relationship.
If the combined use of nicotine-free cigarettes and
NRT is shown to have a positive impact on smoking
cessation and is cost effective, further research would
focus on the implications of the research findings on
policy. Smoking prevalence has changed little in recent
years in New Zealand. Clearly the current range of
smoking cessation aids are not having a strong enough
impact upon smoking cessation rates and consequently
additional options for smokers who want to quit are
needed. This trial will test the balance of benefits and
risks of a new strategy for people to overcome nicotine
dependence. Since smoking is the leading cause of lost
healthy life years in New Zealand [1] if proven effective
this strategy has the potential to have substantial public
health benefits.
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